The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 20, 2024

Filed:

Feb. 25, 2021
Applicant:

Astrazeneca Ab, Södertälje, SE;

Inventor:

Anna Maria Langkilde, Södertälje, SE;

Assignee:

ASTRAZENECA AB, Södertälje, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 9/04 (2006.01); A61K 31/351 (2006.01); A61K 31/70 (2006.01);
U.S. Cl.
CPC ...
A61K 31/70 (2013.01); A61K 31/351 (2013.01); A61P 9/04 (2018.01);
Abstract

The present disclosure is directed to methods of treating patients with heart failure with reduced ejection fraction (HFrEF), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. The methods disclosed herein can reduce the risk of a composite outcome of a first episode of worsening heart failure (hospitalization for heart failure or an urgent heart failure visit) or death from cardiovascular causes. Each of the three components of this composite outcome can also be reduced, as well as the total number of heart failure hospitalizations and deaths from cardiovascular causes. SGLT2 inhibitors, such as dapagliflozin, can also reduce a worsening of heart failure symptoms. The methods disclosed herein can also improve heart failure symptoms, health status, and quality of life.


Find Patent Forward Citations

Loading…